Demethyleneberberine: Multi-Pathway Natural Isoquinoline Alkaloid for Inflammation and Cancer Research

Executive Summary: Demethyleneberberine (DMB) is a natural isoquinoline alkaloid derived from Phellodendron bark and is a major metabolite of berberine. DMB exhibits potent inhibition of NF-κB and MAPK signaling pathways, validated in both in vitro and in vivo models (Zhao et al., 2022). It blocks TLR4-mitochondria signaling and NLRP3 inflammasome-mediated IL-1β maturation, supporting its anti-inflammatory and anti-fibrotic effects. DMB also activates AMPK and inhibits c-Myc/HIF-1α, expanding its utility to neuroprotection and suppression of non-small cell lung cancer (NSCLC) proliferation. Its mechanistic specificity and low toxicity profile are supported by rigorous peer-reviewed studies and product documentation from APExBIO (APExBIO product sheet).

Biological Rationale

Demethyleneberberine (DMB, CAS No. 25459-91-0) is a natural isoquinoline alkaloid obtained from traditional Chinese medicinal sources, notably Phellodendron bark (APExBIO). DMB is a primary metabolite of berberine, itself a well-studied compound for metabolic and anti-inflammatory applications. DMB's biological rationale is anchored in its multi-modal inhibition of inflammation, as demonstrated in ulcerative colitis (UC), autoimmune hepatitis, and non-small cell lung cancer (NSCLC) models. It disrupts key inflammatory signaling cascades, maintains mitochondrial homeostasis, and modulates immune cell responses in vitro and in vivo (Zhao et al., 2022). The compound's low toxicity and robust pharmacological profile make it a preferred tool for mechanistic studies in inflammation, fibrosis, neurodegeneration, and cancer (Mechanistic Rationale—this article expands the depth of mechanistic evidence and specific workflow parameters beyond the summary provided).

Mechanism of Action of Demethyleneberberine

DMB exhibits broad-spectrum inhibition of inflammatory and oncogenic pathways. It potently inhibits the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase) signaling cascades, both central to inflammatory cytokine production and cellular proliferation (Multi-Pathway Alkaloid—this article provides updated quantitative parameters and comparative benchmarks). DMB also blocks the TLR4 (Toll-like receptor 4)-mitochondria axis, restricting mitochondrial biosynthesis and homeostasis that drive IL-1β maturation. Furthermore, it inhibits NLRP3 inflammasome activation, thereby blocking caspase-1 dependent cleavage of pro-IL-1β to its active form (Zhao et al., 2022). Additional effects include reversible inhibition of monoamine oxidase B (MAO-B) and downregulation of c-Myc/HIF-1α, with concurrent AMPK pathway activation, supporting anti-fibrotic and neuroprotective outcomes. These mechanisms are validated across RAW264.7 macrophages (inflammation), A549/NSCLC cells (cancer), and HcoEpiC colonic epithelial cells (distribution studies).

Evidence & Benchmarks

• In vitro, DMB inhibits LPS-induced inflammatory cytokine release in RAW264.7 macrophages at 10–20 μM, reducing IL-1β maturation by suppressing TLR4-mitochondria signaling (Zhao et al., 2022, Fig. 4–5).
• DMB induces G1-phase cell cycle arrest and cellular senescence in A549 NSCLC cells at 80 μM after 24–48 hours, with reduced proliferation markers and increased β-galactosidase activity (Versatile Inhibitor Dossier—this article quantifies the cell cycle and senescence endpoints in direct comparison to peer compounds).
• In vivo, oral administration of DMB at 100–200 mg/kg/day improves clinical and histological metrics in DSS-induced mouse ulcerative colitis models, with significant reductions in colon atrophy, neutrophil infiltration, and tissue damage after 7–14 days (Zhao et al., 2022, Table 2).
• Intraperitoneal DMB (7.5–30 mg/kg/day) suppresses autoimmune hepatitis progression in murine models, attenuating inflammatory liver injury and fibrosis markers (Multi-Pathway NF-κB Inhibitor—this article refines the workflow benchmarks for animal dosing and toxicity evaluation).
• DMB demonstrates reversible MAO-B inhibition in neurodegeneration models, with IC₅₀ values measured in the low micromolar range, supporting its potential in Parkinson's and Huntington's disease research (Benchmark Dossier—this piece details MAO-B and AMPK modulation; here we clarify application boundaries and solubility parameters).
• Acute and chronic dosing studies (up to 98 days, 50 mg/kg/d) report no observable toxicity or adverse effects in murine models (Zhao et al., 2022, Safety Assessment).

Applications, Limits & Misconceptions

• DMB is validated for anti-inflammatory effects in cell-based and animal models of ulcerative colitis, autoimmune hepatitis, and NSCLC.
• It is an effective tool for studying TLR4, NLRP3, and mitochondrial-dependent signaling in innate immunity and inflammation.
• DMB supports research in neurodegenerative disease models via MAO-B inhibition and AMPK activation.
• It is not recommended as a direct clinical candidate or for use in human therapeutic protocols due to lack of human clinical trial data.
• Solubility is optimal in DMSO (≥50.1 mg/mL) and ethanol (≥2.57 mg/mL with warming and sonication); it is insoluble in water.

Common Pitfalls or Misconceptions

• DMB is not water-soluble; attempts to dissolve in aqueous buffers without a co-solvent will result in precipitation and unreliable dosing.
• It is not a direct substitute for berberine; mechanistic and metabolic profiles differ, particularly regarding mitochondrial and inflammasome modulation.
• Human use is not validated; current evidence is preclinical, and DMB is not approved for therapeutic applications in humans.
• Short-term storage in solution is recommended; prolonged storage, especially above -20°C or in non-airtight vials, may result in compound degradation.
• Effective concentrations are cell type and endpoint specific; exceeding recommended doses may induce off-target effects or cytotoxicity (e.g., >80 μM in sensitive cell lines).

Workflow Integration & Parameters

DMB (APExBIO SKU N2087) is supplied at ~98% purity and should be stored at -20°C. For cell culture, dissolve in DMSO at stock concentrations up to 50 mg/mL. For RAW264.7 macrophages and A549/NSCLC cells, use working concentrations of 10–80 μM for anti-inflammatory, cell cycle, and senescence studies. For HcoEpiC colonic epithelial cells, concentrations up to 2 mM are used for compound distribution and uptake analyses.

In animal models, oral dosing of 100–200 mg/kg/day is effective for ulcerative colitis protocols; intraperitoneal injection (7.5–30 mg/kg/day) is used for autoimmune hepatitis; and intratumoral injections (50 mg/kg/day) are suitable for NSCLC xenograft studies. Compound solutions should not be stored long-term. DMB is incompatible with water-based vehicles; use DMSO or ethanol with gentle warming and ultrasonic treatment for dissolution. Toxicity studies support safety at chronic doses up to 98 days in mice. For additional mechanistic and application details, see the Demethyleneberberine product page.

Conclusion & Outlook

Demethyleneberberine (DMB) is a mechanistically validated, multi-pathway inhibitor suitable for modern inflammation, neurodegeneration, and cancer research workflows. Its specificity for NF-κB, MAPK, TLR4-mitochondria, and NLRP3 signaling, combined with a favorable safety profile and optimal solubility in DMSO, position DMB as a versatile tool for rigorous preclinical studies. Future research will clarify its translational potential and optimize protocol parameters for emerging disease models. For comprehensive protocols and updates, consult APExBIO's official product documentation and curated peer-reviewed sources.